Patents by Inventor Denton Wade Hoyer

Denton Wade Hoyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
    Patent number: 10730862
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 4, 2020
    Assignees: Yale University, Glaxosmithkline Intellectual Property Development, Cambridge Enterprise Limited University of Cambridge
    Inventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Denton Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le
  • Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
    Publication number: 20190127359
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: December 18, 2018
    Publication date: May 2, 2019
    Inventors: CRAIG M. CREWS, DENNIS BUCKLEY, ALESSIO CIULLI, WILLIAM L. JORGENSEN, PETER C. GAREISS, INGE VAN MOLLE, JEFFREY GUSTAFSON, HYUN-SEOP TAE, JULIEN MICHEL, DENTON WADE HOYER, ANKE G. ROTH, JOHN DAVID HARLING, IAN EDWARD DAVID SMITH, AFJAL HUSSAIN MIAH, SEBASTIEN ANDRE CAMPOS, JOELLE LE
  • Hydroxamic acid derivatives useful as antibacterial agents
    Patent number: 9340493
    Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L1-L4, A, B, R1-R4, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: May 17, 2016
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Charles Francis Donovan, Edmund Lee Ellsworth, Denton Wade Hoyer, Timothy Allan Johnson, Manjinder Singh Lall, Chris Limberakis, Sean Timothy Murphy, Debra Ann Sherry, Clarke Bentley Taylor, Joseph Scott Warmus
  • Hydroxamic Acid Derivatives Useful As Antibacterial Agents
    Publication number: 20140206651
    Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L1-L4, A, B, R1-R4, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.
    Type: Application
    Filed: March 24, 2014
    Publication date: July 24, 2014
    Applicant: Pfizer Inc.
    Inventors: Matthew Frank Brown, Charles Francis Donovan, Edmund Lee Ellsworth, Denton Wade Hoyer, Timothy Allan Johnson, Manjinder Singh Lall, Chris Limberakis, Sean Timothy Murphy, Debra Ann Sherry, Clarke Bentley Taylor, Joseph Scott Warmus
  • Antibacterial agents
    Publication number: 20070191333
    Abstract: Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.
    Type: Application
    Filed: November 18, 2004
    Publication date: August 16, 2007
    Inventors: Kim Marie Hutchings, Jackie Diane Kendall, Sean Timothy Murphy, Tuan Phong Tran, Edmund Lee Ellsworth, Denton Wade Hoyer, Jeremy Tyson Starr
  • Kinase inhibitors
    Patent number: 7196090
    Abstract: This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula: that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis, as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: March 27, 2007
    Assignee: Warner-Lambert Company
    Inventors: Cleo J. Chivikas Connolly, Christopher James Deur, James Marino Hamby, Denton Wade Hoyer, Chris Limberakis, Jessica Elizabeth Reed, Mel Conrad Schroeder, Clarke Taylor
  • Kinase inhibitors
    Publication number: 20040019210
    Abstract: This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula: 1
    Type: Application
    Filed: July 17, 2003
    Publication date: January 29, 2004
    Inventors: Cleo J. Chivikas Connolly, Christopher James Deur, James Marino Hamby, Denton Wade Hoyer, Chris Limberakis, Jessica Elizabeth Reed, Mel Conrad Schroeder, Clarke Taylor
  • Certain thiol inhibitors of endothelin-converting enzyme
    Patent number: 6613782
    Abstract: Disclosed as endothelin converting enzyme inhibitors are the compounds of the formula wherein the variables have the meanings as defined hereinbefore.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: September 2, 2003
    Assignee: Novartis AG
    Inventors: Stéphane De Lombaert, Cynthia Anne Fink, Fariborz Firooznia, Denton Wade Hoyer, Arco Yingcheu Jeng
  • Certain thiol inhibitors of endothelin-converting enzyme
    Patent number: 6423727
    Abstract: Disclosed as endothelin converting enzyme inhibitors are the compounds of the formula wherein the variables have the meanings as defined hereinbefore.
    Type: Grant
    Filed: October 16, 2000
    Date of Patent: July 23, 2002
    Assignee: Novartis AG
    Inventors: Stéphane De Lombaert, Cynthia Anne Fink, Fariborz Firooznia, Denton Wade Hoyer, Arco Yingcheu Jeng
  • Certain thiol inhibitors of endothelin-converting enzyme
    Publication number: 20020082218
    Abstract: Disclosed as endothelin converting enzyme inhibitors are the compounds of the formula 1
    Type: Application
    Filed: February 21, 2002
    Publication date: June 27, 2002
    Inventors: Stephane De Lombaert, Cynthia Anne Fink, Fariborz Firooznia, Denton Wade Hoyer, Arco Yingcheu Jeng